Concepedia

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

Andrew Blauvelt, Melinda Gooderham, Lars Iversen, Susan Ball, Lu Zhang, Noah Agada, Kristian Reich

Journal of the American Academy of Dermatology · 2017 · 111 citations · 14 references

DOIFull text

Open access

Abstract

Ixekizumab is well tolerated and demonstrates persistent efficacy through 108 weeks.

References

14

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 818 citations · Full text

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 815 citations

, , +5

Multiple Imputation for Nonresponse in Surveys.

R. A. Sugden, D. B. Rubin · Journal of the Royal Statistical Society Series A (Statistics in Society) · 1988 · 703 citations

, , +9

Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

Richard G. Langley, Charles N. Ellis · Journal of the American Academy of Dermatology · 2004 · 586 citations

, , +8

Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis

Phoebe Rich, Richard K. Scher · Journal of the American Academy of Dermatology · 2003 · 511 citations

, , +6